Roquefort Therapeutics (LON:COIL) Stock Price Up 2.9% – What’s Next?

Roquefort Therapeutics plc (LON:COIL) shares rose 2.9% during mid-day trading on Thursday . The stock traded as high as GBX 9 and last traded at GBX 9. 119,793 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 209,281 shares. The stock had previously closed at GBX 8.75.

Roquefort Therapeutics Stock Performance

The stock has a fifty day moving average of GBX 9.59 and a 200-day moving average of GBX 9.61. The firm has a market capitalization of £38.41 million, a P/E ratio of -0.41 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.63 and a debt-to-equity ratio of 8.18.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.